Two squirts of a nasal spray, and aged mice started remembering things they had forgotten. That is the headline result from a peer-reviewed study published in the Journal of Extracellular Vesicles in April 2026, led by neuroscientist Ashok K. Shetty at Texas A&M University. The spray delivered tiny biological packets harvested from human neural stem cells directly into the brains of old mice, where they quieted the chronic inflammation linked to memory loss and cognitive decline. The animals performed better on memory tests within weeks, and the benefits lasted months.
No one can buy this spray at a pharmacy. No human has received it. But the study lands at a moment when multiple research teams are converging on the same idea: that the nose offers a shortcut past one of medicine’s most stubborn obstacles, the blood-brain barrier, and that calming the brain’s overactive immune cells may be the key to protecting memory as we age.
What the mouse studies actually showed
The Texas A&M team gave aged mice two intranasal doses of extracellular vesicles, or EVs. Think of EVs as microscopic envelopes shed by cells, packed with proteins and genetic instructions. These particular EVs came from neural stem cells grown in the lab from reprogrammed human skin cells (a technology called iPSC, or induced pluripotent stem cell derivation). Once sprayed into the nose, the EVs traveled along nerve pathways into the hippocampus, the brain region most critical for forming and retrieving memories.
Inside the hippocampus, the EVs changed the behavior of microglia, the brain’s resident immune cells. In a young, healthy brain, microglia act as custodians: clearing debris, pruning unused connections, and fighting infection. But in aging brains, microglia often become chronically activated, pumping out inflammatory signals that damage the very neurons they are supposed to protect. The Texas A&M study found that the EV treatment dialed down two specific inflammatory pathways, NLRP3 and cGAS-STING, that are known drivers of this destructive cycle. Treated mice showed improved performance on object recognition and novelty detection tasks, standard measures of rodent memory.
A second, independent study strengthens the case. Published in Alzheimer’s Research and Therapy, this experiment used a different mouse model, one genetically engineered to develop Alzheimer’s-like brain plaques and tangles. Intranasal EVs from neural stem cells delayed cognitive decline in those animals and reduced hippocampal inflammation. The researchers also reported that male and female mice responded somewhat differently, a detail that could matter significantly if the therapy ever reaches human trials.
Two independent teams, two different mouse models, and a shared finding: intranasal EVs can reach deep brain structures and tamp down the inflammation tied to memory loss. That kind of convergence is what moves a scientific idea from curiosity to serious research priority.
The nose-to-brain shortcut
For decades, drug developers trying to treat brain diseases have faced a fundamental problem. The blood-brain barrier, a tightly sealed layer of cells lining the brain’s blood vessels, blocks most large molecules from entering. Drugs that work beautifully in a test tube never reach the neurons that need them. This barrier is a major reason why so many Alzheimer’s therapies have failed in clinical trials, even when the underlying biology seemed sound.
The nasal route sidesteps that barrier. Nerve fibers in the upper nasal cavity, particularly the olfactory and trigeminal nerves, project directly into the brain. Molecules sprayed into the nose can hitch a ride along these pathways and arrive in regions like the hippocampus without ever passing through the bloodstream. A small human imaging study at Wake Forest University demonstrated this principle using radiolabeled insulin: PET scans of 16 older adults showed that intranasally administered insulin reached memory-related brain regions, including the hippocampus and frontal cortex. Notably, uptake patterns differed between cognitively healthy participants and those with mild cognitive impairment, suggesting that disease progression may affect how well nasal delivery works.
Other groups are exploiting the same route with different cargo. Researchers at the University of Texas Medical Branch developed a nasal spray carrying an anti-tau antibody called TTCM2 and reported cognitive improvements in aged mice that accumulate the abnormal tau protein found in Alzheimer’s brains. And a study in Nature Neuroscience found that foralumab, a nasal anti-CD3 monoclonal antibody originally tested for traumatic brain injury, calmed overactive microglia through a mechanism involving regulatory T cells and the anti-inflammatory signal IL-10. The injury context differs from aging, but the shared biology of microglial overactivation draws a clear line between these programs.
Why this is not a treatment yet
The distance between a successful mouse experiment and a medicine people can use is vast, and most candidates never cross it. The EV nasal spray has not been tested in a single human being. No dose has been established for people. No safety profile exists. The Texas A&M team has not publicly disclosed a timeline for a first-in-human trial.
Even the most promising mouse results routinely fail to translate. Rodent brains are smaller, less complex, and age over months rather than decades. The immune architecture differs. And treatments given to mice at a controlled point in a standardized aging process face a very different challenge in humans, whose neurodegeneration unfolds over years with enormous individual variation.
Manufacturing presents its own hurdles. EVs derived from human stem cells must be produced with extraordinary consistency. Regulators will want to know exactly what is in each batch, how stable the product remains over time, and whether the molecular cargo stays intact from factory to patient. The risk of unintended immune reactions, always a concern with biological products, adds another layer of scrutiny.
Foralumab is further along. A registered clinical trial (NCT06489548) is evaluating the safety of intranasal foralumab in people with Alzheimer’s disease, with outcome measures that include microglial activation markers and cognitive endpoints. But this is a safety-focused study, not a trial designed to prove the drug improves memory or slows decline. The path from a Phase I safety study to an approved therapy typically spans years and requires multiple large, randomized trials comparing the drug to a placebo.
Readers familiar with recently approved Alzheimer’s antibodies like lecanemab and donanemab should note that those drugs target amyloid plaques through intravenous infusion and work by a fundamentally different mechanism. The intranasal EV approach targets neuroinflammation rather than amyloid clearance. Whether calming microglia proves as effective, more effective, or complementary to plaque removal is a question no existing data can answer.
Sex differences and unanswered questions
The Alzheimer’s Research and Therapy study flagged that male and female mice did not respond identically to intranasal EV treatment. This is not surprising. Sex hormones influence microglial behavior, and baseline levels of brain inflammation differ between sexes in both mice and humans. But the finding raises practical questions: Would men and women need different doses? Different timing? Would one sex benefit more than the other? Any future human trial will need to enroll enough participants across sex and gender categories to detect these differences reliably.
Durability is another open question. In the Texas A&M study, cognitive improvements persisted for months after just two doses, a substantial fraction of a mouse’s roughly two-year lifespan. Whether a similar ratio would hold in humans is unknown. People might need repeated treatments, raising questions about long-term safety, adherence, and cost. It is also unclear whether this kind of therapy would work best as a preventive measure, given before symptoms appear, or as a treatment for people who already have noticeable memory problems.
What this means right now
No intranasal spray for brain aging or Alzheimer’s disease is available as an approved therapy as of May 2026. Over-the-counter nasal products marketed for “brain health” are not backed by the kind of rigorous preclinical data described here, and consumers should not assume those products deliver EVs, antibodies, or other complex biologics to the brain in any controlled fashion.
What has changed is the strength of the preclinical signal. Multiple independent research groups, using different therapeutic agents and different animal models, are finding that the nose can serve as a viable delivery route to the brain and that quieting chronically inflamed microglia produces measurable cognitive benefits in aged animals. That convergence is what separates this line of research from the many one-off findings that never go anywhere.
The next few years will determine whether the promise holds. Human safety trials for foralumab are underway. EV manufacturing and characterization work is advancing. And the biological rationale, that chronic microglial inflammation is a treatable driver of cognitive aging, is gaining support from multiple directions. Whether any of these nasal sprays ultimately helps a person remember where they left their keys, or holds off the progression of Alzheimer’s disease, remains a question only human trials can answer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
